February 26, 2020 / 10:38 PM / a month ago

BRIEF-Gilead Sciences Initiates Two Phase 3 Studies Of Investigational Antiviral Remdesivir For The Treatment Of Covid-19

Feb 26 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES INITIATES TWO PHASE 3 STUDIES OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR THE TREATMENT OF COVID-19

* GILEAD SCIENCES INC - U.S. FDA GRANTS INVESTIGATIONAL NEW DRUG AUTHORIZATION TO STUDY REMDESIVIR FOR TREATMENT OF COVID-19

* GILEAD SCIENCES INC - GILEAD STUDIES WILL EVALUATE TWO DOSING DURATIONS OF REMDESIVIR.

* GILEAD SCIENCES INC - RANDOMIZED, OPEN-LABEL, MULTICENTER STUDIES WILL ENROLL APPROXIMATELY 1,000 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below